JC10 Rec'd PCT/PTO 2 2 APR 2005

PTO-1390 (Rev. 02-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it displays a valid OMB control number.

TRANSMITTAL LETTER TO THE UNITED STATES ATTTORNEY'S DOCKET NUMBER 0470-051244							
	DESIGNATED/ELECTED		U.S. APPIACO (10) HO. THO WIT SO 33 CFR 1.5)				
		ON UNDER 35 U.S.C. 371 INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED				
INTERNATIONAL APPLICATION NO. PCt/NL2003/000718		23.10.2003 (October 23, 2003)	23.10.2002 (October 23, 2002)				
	TITLE OF INVENTION						
Pharmaceutical Compositions Comprising Estetrol Derivatives for Use in Cancer Therapy APPLICANT(S) FOR DO/EO/US							
Herman	Jan Tijmen COELINGH BENNINK	and Evert Johannes BUNSCHOTEN					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:							
1.	This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.						
	This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.						
3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.							
4.	The US has been elected (Article 31).						
5.	A copy of the International Applicatio	n as filed (35 U.S.C. 371(c)(2))					
	a. is attached hereto (required only if not communicated by the International Bureau).						
	b. has been communicated by	the International Bureau.					
	c. is not required, as the appli	cation was filed in the United States Receive	ing Office (RO/US).				
6.	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).						
	a. is attached hereto.	•					
	b. has been previously submi	itted under 35 U.S.C. 154(d)(4).					
7.	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))						
	a. are attached hereto (required only if not communicated by the International Bureau).						
	b. have been communicated by the International Bureau.						
į	c. have not been made; however, the time limit for making such amendments has NOT expired.						
	d. have not been made and	will not be made.					
8.	An English language translation of the	he amendments to the claims under PCT Ar	ticle 19 (35 U.S.C. 371(c)(3)).				
9. 🔲	An oath or declaration of the inventor	r(s) (35 U.S.C. 371(c)(4)).					
10.	An English language translation of th Article 36 (35 U.S.C. 371(c)(5)).	e annexes of the International Preliminary E	examination Report under PCT				
Items 11 to 20 below concern document(s) or information included:							
11.	An Information Disclosure Statement	under 37 CFR 1.97 and 1.98.					
12	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.						
13.	A preliminary amendment.						
14. 📙	An Application Data Sheet under 37 CFR 1.76.						
15	A substitute specification.						
16.	A power of attorney and/or change o	f address letter.					
17.	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821- 1.825.						
18. 🗹	A second copy of the published International Application under 35 U.S.C. 154(d)(4).						
19.	A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).						

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Other items or information:

Page 1 of 2

PTO-1390 (Rev. 02-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICAT	ION NO. (if know	n, see 37 CFR 1.5	international ap	PLICATION NO.	ATTORNEY'S DOC	CKET NUMBER		
	40/53	32 3 Z U	PCt/NL2003/0007	18	0470-051244			
The following fees have been submitted					CALCULATIONS	PTO USE ONLY		
21. Basic national fee\$300				\$ 300.00				
If International p PCT Article 3	nination fee reliminary examii 3(1)-(4) ns	\$ 200.00						
Search fee (37 C International Sea	rch fee FR 1.445(a)(2)) I nal Searching Au Irch Report prepa	\$ 400.00						
	TOTAL OF 21, 2	22 and 23 =			\$ 900.00			
Sequence lis	e for specification sting or computer 250 for each add		:					
Total Sheets	Extra Sheets		h additional 50 or fraction up to a whole number)	RATE	0			
- 100 =	/50	=		x \$250	\$			
	30.00 for furnishir late (37 CFR 1.49		aration later than 30 months fr	om the earliest	\$ 130.00			
CLAIMS	NUM	BER FILED	NUMBER EXTRA	RATE	\$			
Total claims	2	1 - 20 =	1	x \$50	\$ 50.00			
Independent clai	ms	3 -3=	0	x \$200	\$ 0			
MULTIPLE DEPI	ENDENT CLAIM	S) (if applicable)		+ \$360	\$ 0			
			TOTAL OF ABOVE	E CACULATIONS =	\$ 1,080.00			
Applicant cla	aims small entity	0						
		\$ 1,080.00						
	f \$130.00 for furn late (37 CFR 1.49	\$ 0						
	_	\$ 1,080.00						
	the enclosed as e cover sheet (37	\$ 0						
			TOTAL F	EES ENCLOSED =	\$ 1,080.00			
					Amount to be refunded:	\$		
					Amount to be charged:	\$		
a. A chec	4 000 00							
b. Please charge my Deposit Account No in the amount of \$ to cover the above fees. A duplicate copy of this sheet is enclosed.								
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit t Account No. 23-0650. A duplicate copy of this sheet is enclosed.								
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.								
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.								
SEND ALL CORRESPONDENCE TO:								
William H. Logsdon								
Webb Ziesenheim Logsdon Orkin & Hanson, P.C.								
	436 Seventh Avenue, 700 Koppers Building Pittsburgh, PA 15219-1818 NAME							
Telephone: (412) 471-8815 22,132								
Facsimile: (412) 471-4094 REGISTRATION NUMBER								

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:	ATTORNEY'S DOCKET NUMBER						
Herman Jan Tijmen COELINGH BENNINK Evert Johannes BUNSCHOTEN	470-051244						
PCT/NL2003/000718							
ENTITLED							
"PHARMACEUTICAL COMPOSITIONS COMPRISING ESTETROL DERIVATIVES FOR USE IN CANCER THERAPY"							

To MAIL STOP PCT
Attention: DO/EO/US
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

EXPRESS MAIL CERTIFICATE

"Express Mail" Label Number <u>EV534972091US</u>

Date of Deposit April 22, 2005

I hereby certify that the following attached papers or fees

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/
ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER
35 U.S.C. 371 (original and two (2) copies) and check in amount
of \$1,080.00 for filing fee and surcharge fee for late Declaration
LETTER RECOGNIZING ATTORNEYS
PRELIMINARY AMENDMENT
WO 2004/037269 – FRONT PAGE with ABSTRACT, SPECIFICATION,
CLAIMS and SEARCH REPORT (27 pp.)

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313-1450.

Nora Ann Pastrick
(Typed name of person mailing paper or fee)

Deal June Strick

(Signature of person mailing paper or fee)

Customer No. 28289

Application No. Not Yet Assigned

Paper Dated: April 22, 2005

In Reply to USPTO Correspondence of N/A

Attorney Docket No. 0470-051244

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.

Not Yet Assigned

Applicant

Herman Jan Tijmen COELINGH BENNINK et al.

Filed

: Concurrently Herewith

Title

PHARMACEUTICAL COMPOSITIONS

COMPRISING ESTETROL DERIVATIVES

FOR USE IN CANCER THERAPY

International Application

No. PCT/NL2003/000718

International Filing Date

23 October 2003

Priority Date Claimed

23 October 2002

MAIL STOP PCT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

LETTER RECOGNIZING ATTORNEYS

Sir:

Enclosed are appropriate papers for initiating the national phase of the aboveidentified PCT application, comprising a specification and claims. A Preliminary Amendment is also enclosed.

Please accept the application for purposes of granting a filing date and recognize William H. Logsdon, Barbara E. Johnson and Paul M. Reznick, Registration Nos. 22,132, 31,198 and 33,059, respectively, as attorneys in this application, pending the filing of a formal Declaration and Power of Attorney.

Kindly direct all communications relating to this application to William H. Logsdon.

Respectfully submitted,

WEBB ZIESENHEIM LOGSDON

ORKIN & HANSON, P.C.

William H./Logsdon, Reg. No. 22,132

Attorney for Applicants 700 Koppers Building 436 Seventh Avenue

Pittsburgh, PA 15219-1818 Telephone: 412/471-8815 Facsimile: 412/471-4094